Emergent BioSolutions, based in Gaithersburg, MD announced that the FDA has approved its Anthrasil for treatment of inhalation anthrax in combination with other antibacterial agents.  Anthrasil is an injection made of purified human immune globulin G (IgG) containing polyclonal antibodies against the anthrax toxins and is manufactured from the plasma of healthy individuals vaccinated with Emergent’s BioThrax vaccine. BioThrax and Anthrasil are the only FDA-licensed vaccine and FDA-approved antibody treatment for anthrax disease respectively.  Anthrasil received Orphan Drug designation previously and was developed under a contract with the BARDA (Biomedical Advanced Research and Development Authority, which is under the US Department of Health and Human Services.  Anthrasil has been delivered to and is stored in the U.S. Strategic National Stockpile to facilitate its availability in response to an anthrax emergency.

Related Links:

http://investors.emergentbiosolutions.com/phoenix.zhtml?c=202582&p=irol-newsArticle&ID=2028357